Phase II Trial of 5‐Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer

LESSONS LEARNED. The 5‐fluorouracil, docetaxel, and nedaplatin (UDON) regimen was well tolerated and showed promising antitumor activity in terms of both objective response rate and survival for patients with advanced or recurrent esophageal squamous cell carcinoma in the first‐line setting. UDON ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Hiroto, Kawakami, Hisato, Nonagase, Yoshikane, Takegawa, Naoki, Okuno, Tatsuya, Takahama, Takayuki, Takeda, Masayuki, Chiba, Yasutaka, Tamura, Takao, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369940/
https://www.ncbi.nlm.nih.gov/pubmed/30361422
http://dx.doi.org/10.1634/theoncologist.2018-0653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369940/
https://www.ncbi.nlm.nih.gov/pubmed/30361422
http://dx.doi.org/10.1634/theoncologist.2018-0653

Ejemplares similares